Actively Recruiting
Long-Term Safety and Efficacy Evaluation of Rozanolixizumab in Adults with Ocular Myasthenia Gravis An Open-Label Phase 3 Extension Study
Led by UCB Biopharma SRL · Updated on 2026-10-27
100
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the long-term safety and effectiveness of rozanolixizumab in adults with ocular myasthenia gravis. This Phase 3, open-label extension study focuses on adults who previously received at least one dose of rozanolixizumab or placebo in an earlier trial and aims to monitor treatment effects and safety over an extended period. Participants can start the study in either an Extended Observation Period or a Symptom-driven Cycle, depending on their clinical needs. In Symptom-driven Cycles, treatment with rozanolixizumab is initiated when symptoms worsen, and dosing is decided by the investigators medical judgment. Rozanolixizumab is given by subcutaneous infusion. This approach allows flexible treatment based on disease activity over time. During the study, participants will be closely monitored through scheduled visits involving assessments of safety, including treatment-emergent adverse events over up to two years. Researchers will also measure changes in ocular symptoms and quality of life using various patient-reported outcome scales. The study will track progression to more generalized myasthenia gravis and overall disease impact while ensuring participant safety and adherence to the treatment protocol.
CONDITIONS
Brief Title
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Research Team
U
UCB Cares
U
UCB Cares
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here